Summary
CERT Chart
People also search for
Certara, Inc. (CERT) Q2 2026 Earnings Call Transcript
Certara, Inc. (CERT) Q2 2026 Earnings Call Transcript
Certara Q2 Earnings Call Highlights
Certara NASDAQ: CERT reported second-quarter 2026 revenue of $93.3 million, up 1% year over year, as software growth offset a decline in services revenue. Management reaffirmed its full-year revenue outlook while outlining further changes to its commercial organization, cost structure and artificial intelligence strategy.
Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates
Certara, Inc. (CERT) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago.
Certara, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 191 | $1,185.25 | $1,583.39 | $398.14 | 33.59% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 500 | $4,405 | $4,107.5 | -$297.5 | -6.75% |
| NA Nizar Araji National Bank Of Canada /FI/ | 200 | $4,292 | $1,614 | -$2,678 | -62.4% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 225,932 | $1.51M | $1.85M | $341,476.64 | 22.6% |
| BG Bart Gancher Intech Investment Management LLC | 22,589 | $143,666.04 | $182,293.23 | $38,627.19 | 26.89% |
Certara, Inc. (CERT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Certara, Inc. ever had a stock split?
Certara, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jon Resnick CEO | NASDAQ (NGS) Exchange | 15687V109 CUSIP |
| US Country | 1,546 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Certara, Inc., with its subsidiaries, operates globally to deliver software products and technology-enabled services tailored for biosimulation applications in various stages of drug discovery and development. Specializing in model-informed drug development, their offerings span across biosimulation for pharmacokinetics and pharmacodynamics prediction, regulatory submissions, and market access. Founded in 2008, Certara capitalizes on its profound expertise to serve a wide spectrum of clients, including life sciences and biopharmaceutical companies, research organizations, academic institutions, and regulators across the United States and internationally. The company’s headquarters are located in Princeton, New Jersey, reflecting its deep commitments to innovation and excellence in the biosimulation domain.
Products and Services
- Simcyp Simulator
- Simcyp Biopharmaceutics
- Simcyp Secondary Intelligence
- Phoenix WinNonlin
- Phoenix Hosted
- Phoenix NLME
- Pirana Modeling Workbench
- Pinnacle 21
- Pinnacle 21 Data Exchange
- Metadata Repository
A mechanistic biosimulation platform designed to facilitate the investigational new drug and translational stages by allowing predictions of pharmacokinetics and pharmacodynamics through a comprehensive mechanistic approach.
This tool is employed to identify and refine drug formulations by leveraging advanced biosimulation techniques, ensuring enhanced drug delivery and efficacy.
Integrates toxicology with quantitative analysis of molecular networks and biological changes, aiding in the detection of drug toxicity and adverse drug reactions efficiently.
Offers non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic modeling capabilities, marking it as a pivotal platform for various pharmacological research phases.
Provides users with a secure and validated Certara Amazon Web Services workspace, enabling streamlined drug development processes in a cloud-based environment.
A cutting-edge software for population modeling and simulation, emphasizing nonlinear mixed effects models to support complex pharmacological analyses.
A comprehensive suite designed for advanced pharmacometrics, providing tools for modeling, simulation, and graphical analysis to streamline pharmacological research.
A cloud platform that automates, standardizes, and validates clinical data, ensuring regulatory compliance and efficiency in drug development workflows.
Facilitates the definition of data standards and specifications, encouraging uniformity and precision in clinical data management.
Allows for controlled and standardized data to inform study design, promoting efficiency and effectiveness across the drug development spectrum.
